This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Your saved search

Name of saved search:

Search terms:

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2023 Jan 28;401(10373):268.

doi: 10.1016/S0140-6736(23)00119-8.

No authors listed

Published Erratum

No authors listed. Lancet. 2023.

. 2023 Jan 28;401(10373):268.

doi: 10.1016/S0140-6736(23)00119-8.

No abstract available

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Schlaich MP, et al. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356632 Clinical Trial.